Benralizumab · Fasenra
Monoclonal antibody
Evidence outlook
Approved: Asthma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (5)
- Eosinophilic Granulomatosis with Polyangiitis FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
- Hypereosinophilic Syndrome FASENRA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause.
- Asthma FASENRA (benralizumab) is indicated as an add-on maintenance treatment of adult patients with severe eosinophilic asthma. FASENRA is not indicated for relief of acute bronchospasm or status asthmaticus (see 7 Warnings and Precautions). Eosinophilic granulomatosis with polyangiitis (EGPA) FASENRA is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis. Hypereosinophilic syndrome (HES) FASENRA is indicated as an add-on to standard therapy for the treatment of patients aged 12 years and older with...
- Treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies)
- AsthmaFasenra is indicated as an add on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long acting β agonists (see section 5.1).Eosinophilic granulomatosis with polyangiitis (EGPA) Fasenra is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis. Hypereosinophilic syndrome (HES) Fasenra is indicated as an add on treatment for adult and adolescent patients aged 12 years and older weighing at least 35 kg with inadequately...
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01928771 NCT01928771 · Asthma This randomized, triple-blind, placebo-controlled Phase 3 trial included 1,205 randomized patients (1,204 treated) and was powered for a hard clinical primary endpoint: annual asthma exacerbation rate in the pre-specified eosinophil-high (≥300/uL) subgroup. Both active dosing regimens met the primary endpoint with statistically significant reductions vs placebo (rate ratios 0.55 and 0.49, p<0.001). The design is high-quality and the primary comparison was clearly favorable and significant. Registry: NCT01928771 | 3 | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL (Immediately following the first administration of study drug through Study Week 48.) 2016-04-05 | Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001). | Reliable signal | link ↗ |
View 4 more trials
ANDHI NCT03170271 · Asthma This was a randomized, double-blind, placebo-controlled trial involving 660 participants (431 assigned to benralizumab and 229 to placebo). The primary clinical endpoint was met: benralizumab produced a significantly lower annualized asthma exacerbation rate than placebo (p<0.0001). Registry: NCT03170271 | 3 | Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24) 2019-09-25 | Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24) | Reliable signal | link ↗ |
CALIMA NCT01914757 · Asthma This was a randomized, triple-blind, placebo-controlled trial with 1,306 randomized participants, including 241, 239, and 248 patients in the primary eosinophil subgroup across the two benralizumab schedules and placebo. The hard clinical primary endpoint—annual asthma exacerbation rate—was significantly improved for both benralizumab every 4 weeks and every 8 weeks versus placebo. Registry: NCT01914757 | 3 | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL (Immediately following the first administration of study drug through Study Week 56.) 2016-03 | Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL (Immediately following the first administration of study drug through Study Week 56.): Benralizumab 30 mg q.4 Weeks 0.6 Events/year (95% CI 0.48 to 0.74) | Benralizumab 30 mg q.8 Weeks 0.66 Events/year (95% CI 0.54 to 0.82) | Placebo 0.93 Events/year (95% CI 0.77 to 1.12) | Reliable signal | link ↗ |
NCT02075255 NCT02075255 · Asthma The trial was randomized, triple-blind, placebo-controlled, and included 220 participants, and its clinical primary endpoint was statistically met for both benralizumab regimens. However, no primary-endpoint power calculation is reported in the provided sources, so the evidence is graded moderate rather than strong. Registry: NCT02075255 | 3 | Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control (Week 28) 2016-08-08 | Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control (Week 28): Benralizumab 30 mg q.4 Weeks 75 Percent (95% CI 50 to 83.3) | Benralizumab 30 mg q.8 Weeks 75 Percent (95% CI 60 to 87.5) vs Placebo 25 Percent (95% CI 0 to 33.3) | Partial signal | link ↗ |
NCT02322775 NCT02322775 · Asthma The trial randomized 211 participants to double-blind benralizumab or placebo and used the clinically relevant lung-function measure FEV1 as its primary endpoint; the primary comparison favored benralizumab with p=0.040. It is graded moderate because the available record does not report a power calculation confirming that the enrollment was adequately powered. Registry: NCT02322775 | 3 | Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 (Baseline, Week 4, Week 8 and Week 12) 2015-10-07 | Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (L) at Week 12 (Baseline, Week 4, Week 8 and Week 12): Benralizumab 30 mg Q4W — Baseline: 2.248 Litre (Standard Deviation 0.6062); Week 12: 2.31 Litre (Standard Deviation 0.6702); Change from baseline at Week 12: 0.057 Litre (Standard Deviation 0.2734) vs Placebo — Baseline: 2.246 Litre (Standard Deviation 0.7677); Week 12: 2.261 Litre (Standard Deviation 0.7959); Change from baseline at Week 12: -0.016 Litre (Standard Deviation 0.235) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (35)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (17)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Phase 4 (12)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (3)
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Benralizumab (Fasenra): this drug | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL5RA) on eosinophils/basophils, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC) | Reliable signal | NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24) NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001). | |
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Albuterol (Ventolin) | Approved | Small molecule | Beta-2 adrenergic receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor | Reliable signal | NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056 | |
| Albuterol Sulfate (Amphastar) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Albuterol Sulfate (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | not yet graded | No reviewed efficacy summary in this indication | |
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results). | |
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow) | ApprovedUS marketing discontinued | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | No reviewed efficacy summary in this indication | |
| Budesonide (Pulmicort) | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide (Pulmicort Flexhaler) | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | Partial signal | NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027). | |
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | Partial signal | NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014) NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015) | |
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor | Reliable signal | NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis | |
| Depemokimab | Approved | Monoclonal antibody | IL-5 | Partial signal | NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58) | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414). | |
| Fluticasone Furoate (Arnuity Ellipta) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411) | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321) | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Reliable signal | NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998) | |
| Fluticasone Propionate | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate / Salmeterol (Advair Diskus) | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed | |
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved | Combination | Glucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor | Partial signal | NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) | |
| Levalbuterol (Xopenex HFA) | Approved | — | beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | Weak signal | NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66 NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year | |
| Methylprednisolone | Approved | Small molecule | Glucocorticoid receptor agonist | not yet graded | No reviewed efficacy summary in this indication | |
| Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale) | Approved | Small molecule | Glucocorticoid receptor; Beta-2 adrenergic receptor | Partial signal | NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001. NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001. | |
| Montelukast (Singulair) | Approved | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) | Weak signal | NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin. | |
| Omalizumab (Xolair) | Approved | Monoclonal antibody | IgE (immunoglobulin E), IgE | Weak signal | No reviewed efficacy summary in this indication | |
| Primatene Mist | Approved | Small molecule | Adrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselective | Partial signal | NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64). | |
| Salmeterol (DISKUS) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Terbutaline | Approved | Small molecule | Beta-2 adrenergic receptor (ADRB2) | not yet graded | No reviewed efficacy summary in this indication | |
| Tezepelumab (Tezspire) | Approved | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | Reliable signal | NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39) NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed | |
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Reliable signal | NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5) | |
| Beclomethasone Dipropionate / Formoterol Fumarate | Phase 3 | Small molecule | Glucocorticoid receptor; β2-adrenergic receptor | Reliable signal | NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206) | |
| Felcorekibart | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Fenoterol | Phase 3 | Small molecule | Beta-2 adrenergic receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Fenoterol / Ipratropium Bromide | Phase 3 | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptor | Reliable signal | NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo. | |
| Indacaterol Maleate / Mometasone Furoate | Phase 3 | — | Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016) NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134) | |
| Ipratropium | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | Weak signal | No reviewed efficacy summary in this indication | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | Partial signal | NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010) NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL | |
| Ocankitug | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Oxitropium Bromide (Ba253BINEB) | Phase 3 | Small molecule | Muscarinic acetylcholine receptor (M3) | Weak signal | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Salbutamol HFA-152a | Phase 3 | Small molecule | Beta-2 adrenergic receptor | Weak signal | NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results). | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Vilanterol | Phase 3 | Small molecule | Beta-2 adrenergic receptor | Partial signal | NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) | |
| Glycopyrronium (PT001) | Phase 2/3 | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) | |
| Stapokibart | Phase 2/3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| WIN378 | Phase 2/3 | Monoclonal antibody | TSLP | Weak signal | Featured results are safety only in this race | |
| AK139 | Phase 2 | Multispecific antibody | IL-4 receptor alpha / ST2 | not yet graded | No reviewed efficacy summary in this indication | |
| ARO-RAGE | Phase 2 | RNA / oligonucleotide | RAGE (receptor for advanced glycation end-products) | Weak signal | Featured results are safety only in this race | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| ENV-294 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Freneslerbart / Mevonlerbart | Phase 2 | Monoclonal antibody | Fel d 1 (major cat allergen protein) | Reliable signal | NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083 | |
| Frevecitinib | Phase 2 | Small molecule | JAK1/2/3/TYK2 | Weak signal | No reviewed efficacy summary in this indication | |
| KT-621 | Phase 2 | Small molecule | STAT6 | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 2 | Antibody-derived scaffold | TSLP + IL-13 | Weak signal | Featured results are safety only in this race | |
| PBF-680 | Phase 2 | — | Adenosine A1 receptor | Partial signal | NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1) | |
| Quisovalimab | Phase 2 | Monoclonal antibody | LIGHT (TNFSF14) | Partial signal | NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed | |
| RC1416 | Phase 2 | Multispecific antibody | IL-4 / IL-5 / IL-13 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 27 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fasenra (Benralizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (2)
2028 (1)
February 2028 (1)
What to watch
2029 (2)
2034 (1)
September 2034 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent